AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Director's Dealing 2014

Nov 14, 2014

5229_dirs_2014-11-14_3a48e8dc-689c-4449-a566-f94698a3d9d1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Regulus Therapeutics Inc. (RGLS)
CIK: 0001505512
Period of Report: 2014-11-12

Reporting Person: ASTRAZENECA PLC (10% Owner)
Reporting Person: ASTRAZENECA AB (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-12	COMMON STOCK	S	2000000	$17.00	Disposed	4250000	Indirect

Footnotes

F1: The securities are owned directly by AstraZeneca AB, a wholly-owned, indirect subsidiary of AstraZeneca PLC. AstraZeneca PLC is an indirect beneficial owner of the reported securities.